Rank
815
Alexion Pharmaceuticals
- Revenues ($M)2604
- Revenue Percent Change16.6
- Profits ($M)144
- Profits Percent Change-78
- Assets ($M)13133
- Employees2924
- Market Value — as of March 31, 2016 ($M)31284
- Previous Rank941
- Morning Consult Brand Index
Company Info
| CEO | David R. Brennan |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| HQ Location | New Haven, CT |
| Website | www.alexion.com |
| Years on Fortune 500 List | - |
| Employees | 2,924 |
Key Financials (last fiscal year)
| Revenues ($M) | $2,604 |
| Profits ($M) | $144 |
| Assets ($M) | $13,133 |
| Total Stockholder Equity ($M) | $8,259 |
| Market Value — as of March 31, 2016 ($M) | $31,284 |
Profit Ratios
| Profit as % of Revenues | 5.5% |
| Profits as % of Assets | 1.1% |
| Profits as % of Stockholder Equity | 1.7% |
Earnings Per Share (Last Fiscal Year)
| Earnings Per Share ($) | 67 |
| EPS % Change (from 2014) | -79.4% |
| EPS % Change (5 year annual rate) | 5.2% |
| EPS % Change (10 year annual rate) | - |
Total Return
| Total Return to Investors (2015) | 3.1% |
| Total Return to Investors (5 year, annualized) | 36.5% |
| Total Return to Investors (10 year, annualized) | 43.8% |